Profile: Abbott Laboratories (ABT)
28 Sep 2016
Abbott Laboratories (Abbott), incorporated on March 6, 1900, is engaged in the discovery, development, manufacture and sale of a line of healthcare products. The Company operates in four business segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products and Vascular Products. The Established Pharmaceutical Products segment includes the international sales of a line of branded generic pharmaceutical products. The Diagnostic Products segment includes the sales of a line of adult and pediatric nutritional products. The Nutritional Products includes the sales of diagnostic systems and tests for blood banks, hospitals, commercial laboratories and alternate-care testing sites. The Vascular Products includes the sales of coronary, endovascular, structural heart, vessel closure and other medical device products.
Established Pharmaceutical Products
The Company's products include a range of branded generic pharmaceuticals manufactured across the world and marketed and sold outside the United States. These products are sold directly to wholesalers, distributors, government agencies, healthcare facilities, pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Certain products are co-marketed or co-promoted with other companies. The segment's therapeutic area portfolio of products includes gastroenterology products, women's health products, cardiovascular and metabolic products, pain and central nervous system products, and respiratory drugs and vaccines.
The Company's gastroenterology products include Creon, which is used for the treatment of pancreatic exocrine insufficiency associated with various underlying conditions, including cystic fibrosis and chronic pancreatitis; Duspatal and Dicetel, which are used for the treatment of irritable bowel syndrome or biliary spasm; Heptral, Transmetil, Samyr and Donamet, which are used for the treatment of intrahepatic cholestasis (associated with liver disease) or depressive symptoms, and Duphalac, which is used for regulation of the physiological rhythm of the colon. Its women's health products include Duphaston, which is used for the treatment of various gynecological disorders, and Femoston, which is a hormone replacement therapy for postmenopausal women. The Company's cardiovascular and metabolic products include Lipanthyl and TriCor, which are used for the treatment of dyslipidemia; Teveten and Teveten Plus, which are used for the treatment of essential hypertension, and Physiotens, which is used for the treatment of hypertension, and Synthroid, which is used for the treatment of hypothyroidism. The Company's pain and central nervous system products include Serc, which is used for the treatment of Meniere's disease and vestibular vertigo, and Brufen, which is used for the treatment of pain, fever and inflammation. Its respiratory drugs and vaccines include the anti-infective clarithromycin, and Influvac, which is an influenza vaccine.
The Company's products include a line of diagnostic systems and tests manufactured, marketed, and sold across the world to blood banks, hospitals, commercial laboratories, clinics, physicians' offices, government agencies, alternate-care testing sites, and plasma protein therapeutic companies from Abbott-owned distribution centers, public warehouses and third-party distributors. Its products include immunoassay and clinical chemistry systems, including ARCHITECT and ABBOTT PRISM, with assays used for screening and/or diagnosis for cancer, cardiac, drugs of abuse, fertility, general chemistries, infectious diseases, such as hepatitis and human immunodeficiency virus (HIV), and therapeutic drug monitoring; a line of hematology systems and reagents known as the Cell-Dyn series; the i-STAT point-of-care diagnostic systems and tests for blood analysis; the m2000, an instrument that automates the extraction, purification, and preparation of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA) from patient samples, and detects and measures infectious agents, including HIV, hepatitis B virus (HBV), hepatitis C virus (HCV) and human papillomavirus (HPV); the Vysis FISH product line of genomic-based tests, including the PathVysion HER-2 DNA probe kit and the UroVysion bladder cancer recurrence kit; informatics and automation solutions for use in laboratories, and IRIDICA, an instrument used to identify a range of infection-causing pathogens, including bacteria, fungi, and viruses in ill patients.
The Company's products include a line of pediatric and adult nutritional products manufactured, marketed and sold across the world. The Company's products are marketed and sold directly to customers and to institutions, wholesalers, retailers, healthcare facilities, government agencies, and third-party distributors from Abbott-owned distribution centers or third-party distributors. Its products include various forms of prepared infant formula and follow-on formula, including Similac, Similac Advance, Similac with Iron, Similac Sensitive, Similac Sensitive RS, Go&Grow by Similac, Similac NeoSure, Similac Organic, Similac Special Care, Similac Total Comfort, Similac For Supplementation, Similac with OptiGRO, Isomil Advance, Isomil, Alimentum, Gain, Grow, Similac Qinti and Eleva; adult and other pediatric nutritional products, including Ensure, Ensure Plus, Ensure Muscle Health, Ensure (with Nutrivigor), Ensure Complete, Glucerna, Glucerna Hunger Smart, ProSure, PediaSure, PediaSure Sidekicks, EleCare, Juven, Abound and Pedialyte; nutritional products used in enteral feeding in healthcare institutions, including Jevity, Glucerna 1.2 Cal, Glucerna 1.5 Cal, Osmolite, Oxepa, Freego (Enteral Pump) and Freego sets, and Nepro, and Zone Perfect bars and the EAS family of nutritional brands, including Myoplex and AdvantEdge.
The Company's Vascular products include a range of coronary, endovascular, vessel closure, and structural heart devices for the treatment of vascular disease manufactured, marketed and sold across the world. In the United States, the segment's products are marketed and sold directly to hospitals from Abbott-owned distribution centers and public warehouses. Outside the United States, sales are made either directly to customers or through distributors. Vascular Products segment's products include XIENCE Alpine, Xience Xpedition, Xience Prime, Xience nano, Xience V, and XIENCE Pro and Xience ProX, which are drug-eluting coronary stent systems developed on the Multi-Link Vision platform; Absorb, which is a drug-eluting coronary bioresorbable vascular scaffold; Multi-Link 8, Multi-Link Vision and Multi-Link Mini Vision, which are coronary metallic stents; TREK and Voyager, which are coronary balloon dilatation products; Hi-Torque Balance Middleweight Elite and ASAHI coronary guidewires; MitraClip, which is a percutaneous mitral valve repair system; Supera Peripheral Stent System, which is a peripheral vascular stent system; StarClose SE and Perclose vessel closure devices, and Acculink/Accunet and Xact/Emboshield NAV, which are carotid stent systems.
The products in the Company's other businesses include blood glucose, continuous glucose, and flash glucose monitoring systems, including test strips, sensors, data management decision software, and accessories for people with diabetes, under the FreeStyle brand, and medical devices for the eye, including cataract surgery, laser-assisted in-situ keratomileusis (LASIK) surgery, contact lens care products, and dry eye products. These products are marketed across the world and sold directly to wholesalers, government agencies, private healthcare organizations, healthcare facilities, mail order pharmacies, and independent retailers from Abbott-owned distribution centers and public warehouses. Some of these products are marketed and distributed through distributors. Blood glucose monitoring systems, contact lens care products and dry eye products are also marketed and sold to consumers.
100 Abbott Park Rd
ABBOTT PARK IL 60064-3500
Company Web Links
- BRIEF-Abbott receives FDA approval for the FreeStyle Libre Pro System
- BRIEF-Abbott says malnutrition adds $15.5 bln annually to direct U.S. medical costs
- Disease-related malnutrition costs U.S. $15.5 bln annually - study
- BRIEF-Moody's says expectations for Abbott's ratings unchanged
- Abbott to sell its eye care business to J&J for about $4.33 billion